Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis - results from multicenter observational cohort

Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis - results from multicenter observational cohort

Background: CT-P13, the first biosimilar monoclonal antibody to infliximab (IFX), has previously been confirmed to be efficacious in inducing mucosal healing in ulcerative colitis (UC) patients. The aim of this study was to evaluate the efficacy of CT-P13 therapy in maintaining mucosal healing in UC...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerzők: Bálint Anita
Rutkai Mariann
Kolar Martin
Bortlik Martin
Duricovad Dana
Hruba Veronika
Lukas Milan
Mitrova Katarina
Malickova Karin
Lukas Martin
Szepes Zoltán
Nagy Ferenc
Palatka Károly
Lovas Szilvia
Végh Zsuzsanna
Kürti Zsuzsanna
Csontos Ágnes Anna
Miheller Pál
Nyári Tibor András
Bor Renáta
Milassin Ágnes
Fábián Anna
Szántó Kata
Lakatos Péter László
Molnár Tamás
Farkas Klaudia
Dokumentumtípus: Cikk
Megjelent: 2018
Sorozat:EXPERT OPINION ON BIOLOGICAL THERAPY 18 No. 11
doi:10.1080/14712598.2018.1530758

mtmt:30320964
Online Access:http://publicatio.bibl.u-szeged.hu/15419
Leíró adatok
Tartalmi kivonat:Background: CT-P13, the first biosimilar monoclonal antibody to infliximab (IFX), has previously been confirmed to be efficacious in inducing mucosal healing in ulcerative colitis (UC) patients. The aim of this study was to evaluate the efficacy of CT-P13 therapy in maintaining mucosal healing in UC. Methods: CT-P13 trough levels, antibody positivity, serum inflammatory markers as CRP level, fecal calprotectin at weeks 14 and 54, concomitant steroid and azathioprine therapy at the time of induction therapy and at weeks 14 and 54, previous use of anti TNF drug and the need of dose intensification as possible predictive factors for mucosal healing at week 54 were evaluated in this prospective study. Results: 61 patients had already completed the 54-week treatment period. Mucosal healing was shown in 65.5 % and 62.1 %, complete mucosal healing was present in 31% and 38 % at week 14 and 54, respectively. The median values of CRP, leukocytes, thrombocytes, and albumin showed significant difference between baseline and week 54. Serum antibody positivity was proved in 6.5 % and 19.7 % of cases at week 14 and 54, respectively. Conclusion: Our study confirmed the long-term efficacy of CT-P13 therapy on mucosal healing in UC.
Terjedelem/Fizikai jellemzők:1181-1187
ISSN:1471-2598

Hasonló tételek